Study of the antilymphoma activity of pracinostat reveals different sensitivities of DLBCL cells to HDAC inhibitors

Histone deacetylase inhibitors (HDACis) are antitumor agents with distinct efficacy in hematologic tumors. Pracinostat is a pan-HDACi with promising early clinical activity. However, similar to other HDACis, its activity as a single agent is limited. Diffuse large B-cell lymphoma (DLBCL) includes di...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Adv
Main Authors: Mensah, Afua Adjeiwaa, Spriano, Filippo, Sartori, Giulio, Priebe, Valdemar, Cascione, Luciano, Gaudio, Eugenio, Tarantelli, Chiara, Civanelli, Elisa, Aresu, Luca, Rinaldi, Andrea, Damia, Giovanna, Lovati, Emanuela, Zucca, Emanuele, Stathis, Anastasios, Pietra, Claudio, Bertoni, Francesco
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2021
Assuntos:
Lymphoid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8152508/
https://ncbi.nlm.nih.gov/pubmed/33999145
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020003566
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados